Lung cancer trials in Ireland

In Ireland 27 Also abroad 2733

27 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC) [EMBOLD SCLC-301]
Where
Dublin
Age
18 years and over
People
420 worldwide
Run by
GlaxoSmithKline
See details and how to joinNCT07099898
Phase 3Taking people
DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy
Where
Cork
Age
18 years and over
People
670 worldwide
Run by
Boehringer Ingelheim
See details and how to joinNCT07472517 · EU 2025-520565-51-00
Phase 3Taking people
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
Where
Dublin 18, Dublin 24, Dublin 8
Age
18 years and over
People
1,000 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT06561386 · EU 2024-513682-40-01
Phase 3Taking people
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
Where
Cork, Dublin 24, Dublin 8
Age
18 years and over
People
680 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06623422 · EU 2023-506327-29-00
Phase 3Taking people
A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC)
Where
Cork, Dublin 8, Galway
Age
18 years and over
People
400 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT07541170 · EU 2025-524263-21-01
Phase 3Taking people
A Study to Evaluate the Benefit of Adding Durvalumab After Chemotherapy, Durvalumab and Surgery in Patients With Early-stage, Operable, Non-small Cell Lung Cancer.
Where
Dublin 8, Dublin 9
Age
18 years and over
People
290 worldwide
Run by
ETOP IBCSG Partners Foundation
See details and how to joinNCT06284317 · EU 2023-508773-82-00
Phase 3Taking people
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
Where
Cork, Dublin 24, Dublin 4, Dublin 7, Dublin 9, Galway, Limerick
Age
18 years and over
People
590 worldwide
Run by
Revolution Medicines, Inc.
See details and how to joinNCT06881784 · EU 2024-518154-16-00
Phase 3Taking people
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
Where
Dublin
Age
18 years and over
People
600 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT06793215
Phase 3Taking people
A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
Where
Dublin 7, Dublin 8, Dublin 9
Age
18 years and over
People
850 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT07361497 · EU 2025-523576-23-00
Phase 2Taking people
A Study of Navlimetostat (BMS-986504) Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
Where
Cork, Dublin
Age
18 years and over
People
254 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT07492680
Phase 2/3Taking people
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
Where
Dublin 24, Dublin 8, Dublin 9, Galway, Waterford
Age
18 years and over
People
626 worldwide
Run by
Mirati Therapeutics Inc.
See details and how to joinNCT04613596 · EU 2023-508922-83-00
Phase 1/2Taking people
Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers
Where
Dublin 7, Dublin 8, Dublin 9, Galway
Age
18 years and over
People
364 worldwide
Run by
Synthekine
See details and how to joinNCT05098132 · EU 2025-522632-14-00
Phase 3Taking people
Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
Where
Dublin 8
Age
18 years and over
People
851 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06422143 · EU 2023-510128-66-00
Phase 3Taking people
A Clinical Study to Assess the Efficacy of Adjuvant Immunotherapy With Cemiplimab in Patients With Surgically Removed Non-small Cell Lung Cancer Who Have Not Received Prior Chemotherapy
Where
Cork, Dublin 4, Dublin 8, Dublin 9
Age
18 years and over
People
390 worldwide
Run by
ETOP IBCSG Partners Foundation
See details and how to joinNCT06931717 · EU 2024-519901-36-00
Phase 1/2Taking people
A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
Where
Dublin
Age
18 years and over
People
248 worldwide
Run by
Terremoto Biosciences Inc.
See details and how to joinNCT07109726
Phase 2Taking people
Overcoming Resistance to Immunotherapy Combining Gemcitabine With Ivonescimab in Advanced NSCLC
Where
Dublin 24, Dublin 8, Dublin 9, Galway
Age
18 years and over
People
47 worldwide
Run by
Swiss Cancer Institute
See details and how to joinNCT07158489 · EU 2026-526043-36-00
Phase 3Taking people
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
Where
Cork, Dublin 18, Dublin 7, Dublin 8, Dublin 9
Age
18 years and over
People
630 worldwide
Run by
Mirati Therapeutics Inc.
See details and how to joinNCT06875310 · EU 2024-515698-85-00
Phase 2Taking people
Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer
Where
Dublin 7, Dublin 8, Dublin 9, Galway
Age
18 years to 95 years
People
630 worldwide
Run by
AstraZeneca
See details and how to joinNCT05061550 · EU 2023-508852-21-00
Phase 2Taking people
OPTIMISE Lung SABR
Where
Dublin
Age
18 years and over
People
208
Run by
Cancer Trials Ireland
See details and how to joinNCT07777614
Phase 2Taking people
Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC
Where
Dublin 8
Age
18 years and over
People
120 worldwide
Run by
Pfizer
See details and how to joinNCT07489066 · EU 2025-524825-42-00
Phase 3Taking people
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants with Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
Where
Dublin 24, Dublin 7, Dublin 8, Dublin 9
Age
18 years and over
People
282 worldwide
Run by
F. Hoffmann-La Roche AG
See details and how to join2024-518365-10-00 · EU 2024-518365-10-00
Phase 1Taking people
Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors
Where
Dublin
Age
18 years and over
People
180 worldwide
Run by
Olema Pharmaceuticals, Inc.
See details and how to joinNCT06784193
Phase 1Taking people
A Study of ZW251 in Participants With Advanced Solid Tumors
Where
Dublin
Age
18 years and over
People
140 worldwide
Run by
Zymeworks BC Inc.
See details and how to joinNCT07164313
Phase 3Taking people
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
Where
Cork, Dublin 24, Dublin 4, Dublin 7, Dublin 8, Dublin 9, Galway
Age
18 years and over
People
830 worldwide
Run by
AstraZeneca
See details and how to joinNCT06868277 · EU 2024-517780-24-00
Phase 1Taking people
A Phase 1/1b Study of IAM1363 in HER2 Cancers
Where
Cork, Dublin
Age
18 years and over
People
383 worldwide
Run by
Iambic Therapeutics, Inc
See details and how to joinNCT06253871